Cargando…
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
IMPORTANCE: Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)–...
Autores principales: | VandeVrede, Lawren, La Joie, Renaud, Thijssen, Elisabeth H., Asken, Breton M., Vento, Stephanie A., Tsuei, Torie, Baker, Suzanne L., Cobigo, Yann, Fonseca, Corrina, Heuer, Hilary W., Kramer, Joel H., Ljubenkov, Peter A., Rabinovici, Gil D., Rojas, Julio C., Rosen, Howie J., Staffaroni, Adam M., Boeve, Brad F., Dickerson, Brad C., Grossman, Murray, Huey, Edward D., Irwin, David J., Litvan, Irene, Pantelyat, Alexander Y., Tartaglia, Maria Carmela, Dage, Jeffrey L., Boxer, Adam L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071401/ https://www.ncbi.nlm.nih.gov/pubmed/37010841 http://dx.doi.org/10.1001/jamaneurol.2023.0488 |
Ejemplares similares
-
Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020) -
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023) -
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023) -
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
por: Samudra, Niyatee, et al.
Publicado: (2023) -
Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome
por: Asken, Breton M., et al.
Publicado: (2023)